Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification

View Full Paper
Ask AI
Bookmark
Share

Authors

UHUdo HoltickDSDaniel SchütteKKKarl-Anton Kreuzer

Discussion

Loading...

Member takes

Overview

Observational analysis shows similar outcomes for upfront and pre-treated allogeneic stem cell transplantation in high-riskMDS, suggesting early intervention is beneficial.

Key Points

  • Median overall survival was 123.9 months for upfront transplantation, contrasting with 44.4 months for pre-treated patients in high-risk MDS.
  • Progression-free survival was improved in the upfront group with 71.0 months versus 27.7 months in the pre-treatment group after analysis by Kaplan–Meier.
  • Analysis involved 129 consecutive patients undergoing first allogeneic stem cell transplantation with median follow-up of 23 months.
  • Findings highlight the potential benefit of early allogeneic stem cell transplantation without prior cytoreductive therapy in high-risk MDS.

Cite This Study

Holtick et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e52fhttps://doi.org/10.1182/blood-2025-2505
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  2. 2Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review2025
  3. 3Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes2025 · 1 citations
  4. 4Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes2025
  5. 5Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms2025